Journal
CELL REPORTS
Volume 25, Issue 9, Pages 2524-+Publisher
CELL PRESS
DOI: 10.1016/j.celrep.2018.10.107
Keywords
-
Categories
Funding
- JDRF USA Strategic Research Agreement on Optimizing beta-cell Regeneration grant [2-SRA-2015-60-Q-R]
- Natural Sciences and Engineering Research Council of Canada grant [R-3095A03]
Ask authors/readers for more resources
Human multipotent stromal cells (hMSCs) are one of the most versatile cell types used in regenerative medicine due to their ability to respond to injury. In the context of diabetes, it has been previously shown that the regenerative capacity of hMSCs is donor specific after transplantation into streptozotocin (STZ)-treated immunodeficient mice. However, in vivo transplantation models to determine regenerative potency of hMSCs are lengthy, costly, and low throughput. Therefore, a high-throughput quantitative proteomics assay was developed to screen beta cell regenerative potency of donor-derived hMSC lines. Using proteomics, we identified 16 proteins within hMSC conditioned media that effectively identify beta cell regenerative hMSCs. This protein signature was validated using human islet culture assay, ELISA, and the potency was confirmed by recovery of hyperglycemia in STZ-treated mice. Herein, we demonstrated that quantitative proteomics can determine sample-specific protein signatures that can be used to classify previously uncharacterized hMSC lines for beta cell regenerative clinical applications.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available